Cytokinetics Announces Clinical Trial Data Relating to CK-2017357 to Be Presented at the 64th Annual Meeting of the American Academy of Neurology

April 18, 2012 8:04 PM EDT

Additional Preclinical Trial Data to Be Presented at the 2012 Experimental Biology Conference

SOUTH SAN FRANCISCO, CA, Apr 18, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that one oral presentation and two poster presentations are scheduled to be presented at the 64th Annual Meeting of the American Academy of Neurology, to be held April 21-28, 2012 in New Orleans, LA. In addition, a poster presentation containing preclinical data relating to CK-2017357 is scheduled to be presented at the 2012 Experimental Biology Conference being held April 21-25, 2012 in San Diego, CA.

CK-2017357 is the lead drug candidate that has emerged from the company's skeletal muscle contractility program. CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input and delays the onset and reduces the degree of muscle fatigue.

Oral Presentation at the 64th Annual Meeting of the American Academy of Neurology

Date: Wednesday, April 25, 2012 Presentation Time: 2:00 PM - 3:45 PM Central Daylight Time Presentation #: S25.005 Session: S25: Anterior Horn Title: A Study to Evaluate Safety, and Tolerability of Repeated Doses of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis Presenter: Jeremy M. Shefner, MD, PhD, Professor and Chair, Department of Neurology at the Upstate Medical University, State University of New York

Poster Presentation at the 64th Annual Meeting of the American Academy of Neurology

Date: Wednesday, April 25, 2012 Presentation Time: 7:30 AM - 9:00 AM Central Daylight Time (poster displayed 7:30 AM - 12:00 PM) Poster #: P04.155 Session: P04: Anterior Horn: Therapeutics Title: A Study to Evaluate Safety and Tolerability of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis Using a Twice-Daily, Dose-Titration Regimen Presenter: Jeremy M. Shefner, MD, PhD, Professor and Chair, Department of Neurology at the Upstate Medical University, State University of New York

Date: Wednesday, April 25, 2012 Presentation Time: 5:30 PM - 7:00 PM Central Daylight Time (poster displayed 2:00 PM - 7:00 PM) Poster #: P05.169 Session: P05: Anterior Horn: Basic Science Title: The Fast Skeletal Troponin Activator, CK-2017357, Increases Muscle Function and Survival in SOD1 (G93A) Mice; a Model of ALS Presenter: Fady I. Malik, MD, PhD, FACC, Cytokinetics, South San Francisco, CA

Poster Presentation at 2012 Experimental Biology Conference:

Date: Wednesday, April 25, 2012 Presentation Time: 12:30 PM - 2:45 PM Pacific Daylight Time (poster displayed 7:30 AM - 5:30 PM)

Abstract #: S85 1121.7 Title: The Fast Skeletal Troponin Activator, CK-2017357, Improves Resistance to Fatigue in Healthy, Conscious Rats

Presenter: Adam R. Kennedy, PhD, Cytokinetics, South San Francisco, CA

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which CK-2017357 demonstrated potentially clinically relevant pharmacodynamic effects in a Phase IIa trial. Cytokinetics is also conducting research of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as bronchoconstriction associated with asthma and chronic obstructive pulmonary disorder (COPD). All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contact: [

Jodi L. Goldstein
Manager, IR, Corporate Communications & Marketing
(650) 624-3000

SOURCE: Cytokinetics, Inc.